Business

PacBio and Radboud University Medical Center Team Up for New Discoveries in Rare Disease Research

Collaboration Aims to Show Utility and Cost Effectiveness of HiFi Sequencing in Clinical Research Settings, Using Revio Systems MENLO PARK, Calif., June 14,

articlePacific Biosciences Of California, Inc.June 14, 20233/company/pacific-biosciences-of-california/news/pacbio-and-radboud-university-medical-center-team-up-for-new-discoveries-in-rare
PacBio and Radboud University Medical Center Team Up for New Discoveries in Rare Disease Research

About this update from Pacific Biosciences Of California, Inc.

[{"type":"text","content":"Collaboration Aims to Show Utility and Cost Effectiveness of HiFi Sequencing in Clinical Research Settings, Using Revio Systems\nMENLO PARK, Calif., June 14, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions today announced a clinical research study with Radboud University Medical Center (Radboudumc) to explore genetic causes of rare and genetic diseases. Together with Radboud's Department of Human Genetics, which is one of the largest academic centers for human genetics in Europe, PacBio aims to uncover genetic origins of rare and genetic diseases. The study will also explore the feasibility and cost effectiveness of using PacBio's HiFi sequencing technology as part of routine clinical use.\n\n \n \n \n \n \n \n\n \n\"We believe this study is designed to make significant discoveries in the field of medical genetics, and we can't wait to see the results,\" said Christian Henry, President and Chief Executive Officer of PacBio. \"Currently, the genetic basis of 50 percent of rare diseases remain unsolved due to lack of accuracy and depth of current testing workflows. We have joined forces with Radboudumc to better understand this critical gap by using our powerful Revio sequencing systems to identify key variants at scale with extraordinary accuracy. This research not only has the potential to help revolutionize patient care for thousands of individuals each year, but we believe it will also deepen our understanding of the practical application of long-read sequencing technology in routine clinical use. Our collaboration with Radboudumc perfectly aligns with their world-class research capabilities, and we're thrilled to work together to make a real difference in providing answers for families.\"\nRadboudumc scientists are taking on the challenge of solving some of the most puzzling cases of undiagnosed rare diseases using PacBio's HiFi long-read sequencing technology for whole genome sequencing (WGS). Despite having undergone all standard-of-care methods, including short-read sequencing, these individuals still need answers. By studying the potential consolidation of standard molecular tests into a clinical workflow with PacBio HiFi WGS, the project aims to explore PacBio's technology as a potential first-line assay, which could pave the way for a more efficient a...

More updates from Pacific Biosciences Of California, Inc.